Key facts
- Delphyr’s last known valuation is $2.7M (Jun 2024).
- It has raised $2.6M; the latest was Early Stage VC ($2.1M) in Mar 2026.
- Notable investors include Innovatiefonds Noord-Holland, Thomas Wolf, Clément Delangue, Julien Chaumond, LENOS Equity — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Delphyr
- ·The full record, as it builds
Funding rounds
No funding rounds for Delphyr are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Delphyr
Developer of an artificial intelligence-driven medical data platform designed to enable patient-level data analytics for clinicians. The company's platform offers an intuitive interface, real-time access to patient information, and integration with existing healthcare systems, enabling healthcare professionals to save time, improve patient outcomes, and reduce hospital costs.
- Sector
- Healthcare
- HQ
- Amsterdam, Netherlands
- Founded
- 2023
- Employees
- 9
- Website
- delphyr.ai/
- Ownership
- Privately Held (backing)
Delphyr doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Delphyr shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Delphyr in its N-PORT filings yet. We sweep new filings monthly.